Rollout of the 2022/2023 Seasonal Influenza Vaccination and Correlates of the Use of Enhanced Vaccines Among Italian Adults

Overview

Journal Vaccines (Basel)

Date 2023 Dec 23

PMID 38140153

Authors

Luca Pestarino

Alexander Domnich

Andrea Orsi

Federico Bianchi

Elisa Cannavino

Pier Claudio Brasesco

Gianluca Russo

Simone Valbonesi

Giacomo Vallini

Matilde Ogliastro

Giancarlo Icardi

Affiliations

Soon will be listed here.

Abstract

In Italy, several types of seasonal influenza vaccines (SIVs) are available for older adults, but for the 2022/2023 season there were no guidelines on their specific use. This cross-sectional study assessed the frequency and determinants of the use of enhanced (adjuvanted and high-dose) SIVs in Italian older adults, as compared to standard-dose non-adjuvanted formulations. Of 1702 vaccines administered to a representative outpatient sample of adults aged ≥ 60 years and residing in Genoa, 69.5% were enhanced SIVs. Older age (adjusted odds ratio (aOR) for each 1-year increase 1.10; < 0.001), and the presence of cardiovascular disease (aOR 1.40; = 0.011) and diabetes (aOR 1.62; = 0.005) were associated with the use of enhanced vaccines. Compared with the adjuvanted SIV, subjects immunized with the high-dose vaccine were older (aOR for each 1-year increase 1.05; < 0.001) and had higher prevalence of respiratory diseases (aOR 1.85; = 0.052). Moreover, usage of the enhanced SIVs was driven by the period of immunization campaign, place of vaccination and physician. Despite their superior immunogenicity and effectiveness, the adoption of enhanced SIVs in Italy is suboptimal, and should be increased. Enhanced formulations are mostly used in the oldest, and in subjects with some co-morbidities.

References

Bianchi F, Stefanizzi P, Cuscianna E, Di Lorenzo A, Migliore G, Tafuri S . Influenza vaccine coverage in 6months-64 years-old patients affected by chronic diseases: A retrospective cohort study in Italy. Hum Vaccin Immunother. 2023; 19(1):2162301. PMC: 10012954. DOI: 10.1080/21645515.2022.2162301. View

Pregliasco F, Sodano L, Mensi C, Selvaggi M, Adamo B, DArgenio P . Influenza vaccination among the elderly in Italy. Bull World Health Organ. 1999; 77(2):127-31. PMC: 2557587. View

Lu Y, Chillarige Y, Izurieta H, Wei Y, Xu W, Lu M . Effect of Age on Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries Aged ≥65 Years. J Infect Dis. 2019; 220(9):1511-1520. DOI: 10.1093/infdis/jiz360. View

Doornekamp L, van Leeuwen L, van Gorp E, Voeten H, Goeijenbier M . Determinants of Vaccination Uptake in Risk Populations: A Comprehensive Literature Review. Vaccines (Basel). 2020; 8(3). PMC: 7563537. DOI: 10.3390/vaccines8030480. View

Domnich A, Cambiaggi M, Vasco A, Maraniello L, Ansaldi F, Baldo V . Attitudes and Beliefs on Influenza Vaccination during the COVID-19 Pandemic: Results from a Representative Italian Survey. Vaccines (Basel). 2020; 8(4). PMC: 7712959. DOI: 10.3390/vaccines8040711. View

Lee J, Lam G, Kevin Yin J, Loiacono M, Samson S . High-dose influenza vaccine in older adults by age and seasonal characteristics: Systematic review and meta-analysis update. Vaccine X. 2023; 14:100327. PMC: 10276206. DOI: 10.1016/j.jvacx.2023.100327. View

Bujang M, Saat N, Tg Abu Bakar Sidik T, Joo L . Sample Size Guidelines for Logistic Regression from Observational Studies with Large Population: Emphasis on the Accuracy Between Statistics and Parameters Based on Real Life Clinical Data. Malays J Med Sci. 2019; 25(4):122-130. PMC: 6422534. DOI: 10.21315/mjms2018.25.4.12. View

Bonanni P, Boccalini S, Zanobini P, Dakka N, Lorini C, Santomauro F . The appropriateness of the use of influenza vaccines: Recommendations from the latest seasons in Italy. Hum Vaccin Immunother. 2017; 14(3):699-705. PMC: 5861775. DOI: 10.1080/21645515.2017.1388480. View

Tanner A, Dorey R, Brendish N, Clark T . Influenza vaccination: protecting the most vulnerable. Eur Respir Rev. 2021; 30(159). PMC: 9488965. DOI: 10.1183/16000617.0258-2020. View

10.

Nicolay U, Heijnen E, Nacci P, Patriarca P, Leav B . Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults ≥65 years of age: Meta-analysis of cumulative clinical experience. Int J Infect Dis. 2019; 85S:S1-S9. DOI: 10.1016/j.ijid.2019.03.026. View

11.

Domnich A, de Waure C . Comparative effectiveness of adjuvanted versus high-dose seasonal influenza vaccines for older adults: a systematic review and meta-analysis. Int J Infect Dis. 2022; 122:855-863. DOI: 10.1016/j.ijid.2022.07.048. View

12.

Boccalini S, Mando Tacconi F, Lai P, Bechini A, Bonanni P, Panatto D . Appropriateness and preferential use of different seasonal influenza vaccines: A pilot study on the opinion of vaccinating physicians in Italy. Vaccine. 2019; 37(7):915-918. DOI: 10.1016/j.vaccine.2018.12.057. View

13.

Grohskopf L, Blanton L, Ferdinands J, Chung J, Broder K, Talbot H . Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season. MMWR Recomm Rep. 2022; 71(1):1-28. PMC: 9429824. DOI: 10.15585/mmwr.rr7101a1. View

14.

Cowling B, Perera R, Valkenburg S, Leung N, Iuliano A, Tam Y . Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial. Clin Infect Dis. 2019; 71(7):1704-1714. PMC: 7289658. DOI: 10.1093/cid/ciz1034. View

15.

Samson S, Leventhal P, Salamand C, Meng Y, Seet B, Landolfi V . Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis. Expert Rev Vaccines. 2019; 18(3):295-308. DOI: 10.1080/14760584.2019.1575734. View

16.

Palache A, Rockman S, Taylor B, Akcay M, Billington J, Barbosa P . Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use. Vaccine. 2021; 39(41):6081-6087. PMC: 8433505. DOI: 10.1016/j.vaccine.2021.08.097. View

17.

Shartouny J, Lowen A . Message in a bottle: mRNA vaccination for influenza. J Gen Virol. 2022; 103(7). PMC: 10027004. DOI: 10.1099/jgv.0.001765. View

18.

Colrat F, Thommes E, Largeron N, Alvarez F . Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature review. Vaccine. 2021; 39 Suppl 1:A42-A50. DOI: 10.1016/j.vaccine.2020.12.036. View

19.

Shinde V, Cho I, Plested J, Agrawal S, Fiske J, Cai R . Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. Lancet Infect Dis. 2021; 22(1):73-84. DOI: 10.1016/S1473-3099(21)00192-4. View

20.

Vezzosi L, Ricco M, Agozzino E, Odone A, Signorelli C . Knowledge, attitudes, and practices of General Practitioners from the Province of Parma (Northern Italy) towards vaccinations in adults ≥ 65 year-old. Acta Biomed. 2019; 90(9-S):71-75. PMC: 7233658. DOI: 10.23750/abm.v90i9-S.8704. View